Table 2.

Phase III first-line trials with PARP inhibitors ± VEGF inhibitors in combination with an immune checkpoint inhibitor (CPI)

Trial name	Trial details (number, completion date)	PARP-inhibitor	Immune checkpoint inhibitor	Chemotherapy	Maintenance
ATHENA (NCT03522246)	N = 1000 December 2024 Recruitment stopped	Rucaparib	Nivolumab	Standard of care (not part of trial)	1. Nivolumab + Rucaparib 2. Nivolumab placebo + Rucaparib 3. Nivolumab + Rucaparib placebo 4. Placebo + Placebo
DUO-O (NCT03737643)	N = 1254 June 2023 Still recruiting	Olaparib	Durvalumab	Somatic BRCA wildtype: 1. CT + Bev + placebo 2. CT + Bev + Durva 3. CT + Bev + Durva Somatic BRCA mutant: 4. CT + Bev (optional) + Durva	tBRCA wildtype: 1. Bev + Durva placebo + Olaparib placebo 2. Bev + Durva + Olaparib placebo 3. Bev + Durva + Olaparib tBRCA mutant: 4. Bev (optional) + Durva + Olaparib
MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036 (NCT03740165)	N = 1086 August 2025 Still recruiting	Olaparib	Pembrolizumab	1. CT + pembrolizumab 2. CT + pembrolizumab 3. CT + placebo	1. Pembro + Olaparib 2. Pembro + placebo 3. Placebo + placebo
ENGOT-0V44 FIRST trial (NCT03602859)	N = 1228 February 2023 Still recruiting	Niraparib	TSR-042 (Dostarlimab)	1. CT + TSR-042 2. CT 3. CT	1. Niraparib + TSR-042 2. Niraparib 3. Placebo

Bev, bevacizumab; CT, chemotherapy; Durva, durvalumab; N, number